Q-omics provides the consensus-scored SNTA1 profile across patient tissues and cancer cell-line models. SNTA1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SNTA1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, SNTA1 protein abundance shows 41,799 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, BLCA, and GBM as cancer lineages where SNTA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNTA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNTA1 survival associations across molecular data types. SNTA1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNTA1 RNA expression–survival associations across cancer types. High SNTA1 expression shows unfavorable associations in UCEC, HNSC, KICH and LUSC, but favorable associations in LUAD and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SNTA1 RNA expression.
This table summarizes SNTA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 13. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SNTA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNTA1 shows lower tumor expression in BLCA, THCA and BRCA and higher tumor expression in KIRC, LIHC and LUAD. The BLCA box plot shows higher SNTA1 RNA expression in normal versus tumor tissue (log2 FC = −2.554, t-test p < 0.001).
This table shows molecular features associated with SNTA1 in patient tissues and cancer cell lines. In patient samples, SNTA1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SNTA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
